Ibrance® (palbociclib) Available Through Onco360
On February 3, 2015, the U.S. Food and Drug Administration (FDA) approved Ibrance as a combination therapy for the treatment of certain types of breast cancer.
Ibrance is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease1.
Breast cancer is the second most common type of cancer among women in the United States. The National Cancer Institute estimates that 232,670 American women are living with advanced breast cancer and 40,000 died from the disease in 20142.
“In the last 12 months, Onco360 has been selected as a network pharmacy provider for 10 limited distribution products, further enhancing our portfolio and reflecting the success of our oncology pharmacy model,” said Paul Jardina, President and Chief Executive Officer of Onco360. “We are pleased to expand our relationship with Pfizer, and we are excited about the resonance and recognition the Onco360 oncology pharmacy model is garnering in the marketplace. As part of our commitment to cancer patients and their healthcare teams, Onco360 will continue to provide the most comprehensive pharmacy and clinical support services possible.”
Ibrance is immediately available for order through Onco360. Information on how to order can be obtained by visiting www.Onco360.com/How To Order.